Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Prospektiv, multicenter, icke-interventionell studie för att undersöka effektiviteten av REKOVELLE® för äggstocksstimulering för asiatiska kvinnor i verkliga miljöer (PROFOUND)

29 september 2026 uppdaterad av: Ferring Pharmaceuticals

Prospektiv, icke-interventionell studie i flera länder för att undersöka REKOVELLE för äggstocksstimulering: effektiviteten, säkerheten och användningsmönster för asiatiska kvinnor i verkligheten

Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Intervention / Behandling

Studietyp

Observationell

Inskrivning (Faktisk)

1526

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Hiroshima, Japan, 7300035
        • Ferring Investigational Site
      • Hokkaido, Japan, 0600003
        • Ferring Investigational Site
      • Hyōgo, Japan, 6500021
        • Ferring Investigational Site
      • Osaka, Japan, 5300011
        • Ferring Investigational Site
      • Osaka, Japan, 5500015
        • Ferring Investigational Site
      • Saitama, Japan, 3540035
        • Ferring Investigational Site
    • Chiba
      • Chiba, Chiba, Japan, 2610023
        • Ferring Investigational Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japan, 8120013
        • Ferring Investigational Site
      • Kitakyushu, Fukuoka, Japan, 8070825
        • Ferring Investigational Site
    • Gunma
      • Takasaki, Gunma, Japan, 3700841
        • Ferring Investigational Site
    • Hiroshima
      • Hiroshima, Hiroshima, Japan, 7320822
        • Ferring Investigational Site
    • Japan
      • Bunkyō City, Japan, Japan, 1130033
        • Ferring Investigational Site
    • Tokyo
      • Tokyo, Tokyo, Japan, 1600023
        • Ferring Investigational Site
      • Busan, Sydkorea, 47245
        • Ferring Investigational Site
      • Seoul, Sydkorea, 02586
        • Maria Fertility Hospital
    • Busan
      • Busan, Busan, Sydkorea, 49241
        • Ferring Investigational Site
    • Daegu
      • Daegu, Daegu, Sydkorea, 41910
        • Ferring Investigational Site
    • Seongnam
      • Seongnam-si, Seongnam, Sydkorea, 13496
        • Ferring Investigational Site
      • Taichung, Taiwan, 406
        • Ferring Investigational Site
      • Taipei, Taiwan, 100225
        • Ferring Investigational Site
      • Taipei, Taiwan, 110
        • Ferring Investigational Site
    • Tainan
      • Tainan, Tainan, Taiwan, 70403
        • Ferring Investigational Site
      • Tainan, Tainan, Taiwan, 71004
        • Ferring Investigational Site
    • Taoyuan
      • Taoyuan, Taoyuan, Taiwan, 333
        • Ferring Investigational Site
      • Bangkok, Thailand, 10700
        • Ferring Investigational Site
    • Muang
      • Phitsanulok, Muang, Thailand, 65000
        • Naresuan University Hospital
    • Ratchathewi
      • Bangkok, Ratchathewi, Thailand, 10400
        • Ramathibodi Hospital
    • Hanoi
      • Hanoi, Hanoi, Vietnam, 100000
        • Ferring Investigational Site
    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
        • Ferring Investigational Site
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • Ferring Investigational Site
    • Huế
      • Huế, Huế, Vietnam, 49000
        • Ferring Investigational Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

20 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

N/A

Kön som är behöriga för studier

Kvinna

Testmetod

Sannolikhetsprov

Studera befolkning

Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.

Beskrivning

Inclusion Criteria:

  • Females aged 20 years or older at enrollment
  • Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
  • Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
  • Participating in an interventional clinical trial in which any medication treatment is mandated
  • Women with a contraindication for prescription of REKOVELLE treatment
  • Oocyte donors
  • Undergoing ovarian stimulation for fertility preservation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
REKOVELLE

Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.

Individualised dosing regiment of REKOVELLE in routine clinical practice.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Cumulative live birth rate
Tidsram: Up to 12 months

Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

Up to 12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The Luteinising hormone (LH) surge suppression protocol
Tidsram: Up to 22 days

Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol.

Up to 22 days
Daily Dosage
Tidsram: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage.

Up to 22 days
Stimulation Duration
Tidsram: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration.

Up to 22 days
Total Dosage
Tidsram: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage.

Up to 22 days
Trigger Protocol
Tidsram: Up to 22 days

Treatment pattern will be measured by analysing the trigger protocol.

Up to 22 days
Luteal phase support protocol
Tidsram: Up to 22 days

Treatment pattern will be measured by analysing the luteal phase support protocol.

Up to 22 days
Number of oocytes retrieved
Tidsram: Up to 22 days

Number of oocytes retrieved at oocyte retrieval

Up to 22 days
Number of Metaphase II (MII) oocytes
Tidsram: Up to 22 days

Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI))

Up to 22 days
Number of embryos
Tidsram: Day 3 after oocyte retrieval

Number of embryos on Day 3 after oocyte retrieved

Day 3 after oocyte retrieval
Number of Blastocysts
Tidsram: Day 5 after oocyte retrieval

Number of Blastocysts on Day 5 after oocyte retrieved

Day 5 after oocyte retrieval
Number of embryos transferred
Tidsram: Up to 28 days

Embryos transferred in fresh and/or frozen transfer cycles

Up to 28 days
Number of blastocysts transferred
Tidsram: Up to 28 days

Blastocysts transferred in fresh and/or frozen transfer cycles

Up to 28 days
Implantation rate
Tidsram: Up to 28 days

Number of gestational sacs, embryos or blastocysts transferred

Up to 28 days
Positive human chorionic gonadotropin (hCG) rate
Tidsram: 11 to 15 days after transfer

Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer

11 to 15 days after transfer
Clinical Pregnancy rate
Tidsram: 4 to 5 weeks after transfer

Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer)

4 to 5 weeks after transfer
Vital Pregnancy
Tidsram: 4 to 5 weeks after transfer

Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer)

4 to 5 weeks after transfer
Ongoing pregnancy rate
Tidsram: 9 to 11 weeks after transfer

Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer)

9 to 11 weeks after transfer
Time to pregnancy
Tidsram: 4 to 5 weeks after transfer

Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy

4 to 5 weeks after transfer
Live birth rate
Tidsram: More than 20 weeks after transfer

Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

More than 20 weeks after transfer
Multiple pregnancy rate
Tidsram: 4 to 5 weeks after transfer

More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer

4 to 5 weeks after transfer
Spontaneous abortion rate
Tidsram: Up to 10-11 weeks after transfer

Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound

Up to 10-11 weeks after transfer
Ectopic pregnancy rate
Tidsram: Up to 10-11 weeks after transfer

Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.

Up to 10-11 weeks after transfer
Estradiol Hormone levels
Tidsram: Up to 20 days

Estradiol hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Progesterone Hormone levels
Tidsram: Up to 20 days

Progesterone hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Cycle cancellation rate and the reason for cycle cancellation
Tidsram: Up to 28 days

Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason)

Up to 28 days
Transfer cancellation rate and the reason for transfer cancellation
Tidsram: Up to 28 days

Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation).

Up to 28 days
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Tidsram: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Frequency and severity of ADRs and SAEs as defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Tidsram: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.

Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer)

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Tidsram: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Number of subjects with mild / moderate / severe OHSS, defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Global Clinical Compliance, Ferring Pharmaceuticals

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

27 augusti 2024

Primärt slutförande (Beräknad)

1 maj 2027

Avslutad studie (Beräknad)

1 augusti 2027

Studieregistreringsdatum

Först inskickad

6 augusti 2024

Först inskickad som uppfyllde QC-kriterierna

16 augusti 2024

Första postat (Faktisk)

20 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 000430

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera